Eli Lilly's oral GLP-1 orforglipron shows weight maintenance success

Chugai Pharmaceutical Co. announced that Eli Lilly and Company, the global development and sales rights holder for orforglipron, has released top-line results from the phase 3 ATTAIN-MAINTAIN trial on December 18, 2025. Orforglipron, an oral GLP-1 receptor agonist originated by Chugai, met its primary and all key secondary endpoints for weight maintenance over 52 weeks when compared to placebo. This followed an initial period of weight reduction with semaglutide or Zepbound.

Participants who switched from semaglutide to orforglipron maintained their achieved weight loss, experiencing an average change of only 0.9kg. Eli Lilly has already submitted an approval application for orforglipron as an obesity treatment to the U.S. Food and Drug Administration (FDA).